Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: Methylphenidate vs. atomoxetine treatments

Behavioural Brain Research

Volumn 244, Issue , 2013, Pages 38-47

  Harvey, Roxann C ^a   Jordan, Chloe J ^a   Tassin, David H ^a   Moody, Kayla R ^a   Dwoskin, Linda P ^b   Kantak, Kathleen M ^a  

^a BOSTON UNIVERSITY   (United States)

^b University of Kentucky   (United States)

Author keywords

Atomoxetine; Attention deficit Hyperactivity disorder; Methylphenidate; Spontaneously hypertensive rat; Strategy set shifting task

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE;

ADOLESCENCE; ANALYTICAL ERROR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENETIC MODEL; HABITUATION; LATENT PERIOD; LEARNING; MALE; MONOTHERAPY; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PERCEPTIVE DISCRIMINATION; PRIORITY JOURNAL; RAT; REINFORCEMENT; RESPONSE TIME; SPONTANEOUSLY HYPERTENSIVE RAT; STRAIN DIFFERENCE; STRATEGY SET SHIFTING TASK; TASK PERFORMANCE; WISTAR KYOTO RAT; WISTAR RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CONDITIONING, OPERANT; DOPAMINE UPTAKE INHIBITORS; MALE; METHYLPHENIDATE; PROPYLAMINES; RATS; REVERSAL LEARNING; SPECIES SPECIFICITY; TIME FACTORS;

EID: 84874368751     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.01.027     Document Type: Article

References (81)

1. Seidman L.J., Valera E.M., Makris N. Structural brain imaging of attention-deficit/hyperactivity disorder. Biological Psychiatry 2005, 57:1263-1272.
2. Castellanos F.X. Anatomic magnetic resonance imaging studies of attention-deficit/hyperactivity disorder. Dialogues in Clinical Neuroscience 2002, 4:444-448.
3. Cubillo A., Halari R., Smith A., Taylor E., Rubia K. A review of fronto-striatal and fronto-cortical brain abnormalities in children and adults with attention deficit hyperactivity disorder (ADHD) and new evidence for dysfunction in adults with ADHD during motivation and attention. Cortex 2012, 48:194-215.
4. Seidman L.J., Biederman J., Faraone S.V., Weber W., Ouellette C. Toward defining a neuropsychology of attention deficit-hyperactivity disorder: performance of children and adolescents from a large clinically referred sample. Journal of Consulting and Clinical Psychology 1997, 65:150-160.
5. Chamberlain S.R., Robbins T.W., Winder-Rhodes S., Muller U., Sahakian B.J., Blackwell A.D., et al. Translational approaches to frontostriatal dysfunction in attention-deficit/hyperactivity disorder using a computerized neuropsychological battery. Biological Psychiatry 2011, 69:1192-1203.
6. Kempton S., Vance A., Maruff P., Luk E., Costin J., Pantelis C. Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children. Psychological Medicine 1999, 29:527-538.
7. Mehta M.A., Goodyer I.M., Sahakian B.J. Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. Journal of Child Psychology and Psychiatry 2004, 45:293-305.
8. Yildiz O., Sismanlar S.G., Memik N.C., Karakaya I., Agaoglu B. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry and Human Development 2011, 42:257-269.
9. Tannock R., Schachar R. Methylphenidate and cognitive perseveration in hyperactive children. Journal of Child Psychology and Psychiatry 1992, 33:1217-1228.
10. Pietrzak R.H., Mollica C.M., Maruff P., Snyder P.J. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neuroscience and Biobehavioral Reviews 2006, 30:1225-1245.
11. Gau S.S., Shang C.Y. Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine. International Journal of Neuropsychopharmacology 2010, 13:243-256.
12. Spencer T., Biederman J., Wilens T., Prince J., Hatch M., Jones J., et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. American Journal of Psychiatry 1998, 155:693-695.
13. Chamberlain S.R., Del Campo N., Dowson J., Muller U., Clark L., Robbins T.W., et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biological Psychiatry 2007, 62:977-984.
14. Wultz B., Sagvolden T., Moser E.I., Moser M.B. The spontaneously hypertensive rat as an animal model of attention-deficit hyperactivity disorder: effects of methylphenidate on exploratory behavior. Behavioral and Neural Biology 1990, 53:88-102.
15. Sagvolden T., Metzger M.A., Schiorbeck H.K., Rugland A.L., Spinnangr I., Sagvolden G. The spontaneously hypertensive rat (SHR) as an animal model of childhood hyperactivity (ADHD): changed reactivity to reinforcers and to psychomotor stimulants. Behavioral and Neural Biology 1992, 58:103-112.
16. Wooters T.E., Bardo M.T. Methylphenidate and fluphenazine, but not amphetamine, differentially affect impulsive choice in spontaneously hypertensive, Wistar-Kyoto and Sprague-Dawley rats. Brain Research 2011, 1396:45-53.
17. Jentsch J.D. Impaired visuospatial divided attention in the spontaneously hypertensive rat. Behavioural Brain Research 2005, 157:323-330.
18. Sagvolden T., Xu T. l-Amphetamine improves poor sustained attention while d-amphetamine reduces overactivity and impulsiveness as well as improves sustained attention in an animal model of attention-deficit/hyperactivity disorder (ADHD). Behavioral and Brain Functions 2008, 4:3.
19. Kantak K.M., Singh T., Kerstetter K.A., Dembro K.A., Mutebi M.M., Harvey R.C., et al. Advancing the spontaneous hypertensive rat model of attention deficit/hyperactivity disorder. Behavioral Neuroscience 2008, 122:340-357.
20. Meneses A., Ponce-Lopez T., Tellez R., Gonzalez R., Castillo C., Gasbarri A. Effects of d-amphetamine on short- and long-term memory in spontaneously hypertensive, Wistar-Kyoto and Sprague-Dawley rats. Behavioural Brain Research 2011, 216:472-476.
21. van den Bergh F.S., Bloemarts E., Chan J.S., Groenink L., Olivier B., Oosting R.S. Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder. Pharmacology Biochemistry and Behavior 2006, 83:380-390.
22. Chess A.C., Raymond B.E., Gardner-Morse I.G., Stefani M.R., Green J.T. Set shifting in a rodent model of attention-deficit/hyperactivity disorder. Behavioral Neuroscience 2011, 125:372-382.
23. Robertson B.A., Clements K.M., Wainwright P.E. The working memory capabilities of the spontaneously hypertensive rat. Physiology and Behavior 2008, 94:481-486.
24. Harvey R.C., Sen S., Deaciuc A., Dwoskin L.P., Kantak K.M. Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function. Neuropsychopharmacology 2011, 36:837-847.
25. Thanos P.K., Ivanov I., Robinson J.K., Michaelides M., Wang G.J., Swanson J.M., et al. Dissociation between spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats in baseline performance and methylphenidate response on measures of attention, impulsivity and hyperactivity in a visual stimulus position discrimination task. Pharmacology Biochemistry and Behavior 2010, 94:374-379.
26. Adriani W., Laviola G. Windows of vulnerability to psychopathology and therapeutic strategy in the adolescent rodent model. Behavioural Pharmacology 2004, 15:341-352.
27. Cao A.H., Yu L., Wang Y.W., Wang J.M., Yang L.J., Lei G.F. Effects of methylphenidate on attentional set-shifting in a genetic model of attention-deficit/hyperactivity disorder. Behavioral and Brain Functions 2012, 8:10.
28. Andersen S.L. Trajectories of brain development: point of vulnerability or window of opportunity?. Neuroscience and Biobehavioral Reviews 2003, 27:3-18.
29. Floresco S.B., Block A.E., Tse M.T. Inactivation of the medial prefrontal cortex of the rat impairs strategy set-shifting, but not reversal learning, using a novel, automated procedure. Behavioural Brain Research 2008, 190:85-96.
30. Ragozzino M.E., Detrick S., Kesner R.P. Involvement of the prelimbic-infralimbic areas of the rodent prefrontal cortex in behavioral flexibility for place and response learning. Journal of Neuroscience 1999, 19:4585-4594.
31. Birrell J.M., Brown V.J. Medial frontal cortex mediates perceptual attentional set shifting in the rat. Journal of Neuroscience 2000, 20:4320-4324.
32. Stefani M.R., Groth K., Moghaddam B. Glutamate receptors in the rat medial prefrontal cortex regulate set-shifting ability. Behavioral Neuroscience 2003, 117:728-737.
33. Boulougouris V., Dalley J.W., Robbins T.W. Effects of orbitofrontal, infralimbic and prelimbic cortical lesions on serial spatial reversal learning in the rat. Behavioural Brain Research 2007, 179:219-228.
34. Ghods-Sharifi S., Haluk D.M., Floresco S.B. Differential effects of inactivation of the orbitofrontal cortex on strategy set-shifting and reversal learning. Neurobiology of Learning and Memory 2008, 89:567-573.
35. American Academy of Pediatrics Committee on Children With Disabilities and Committee on Drugs Medication for children with attentional disorders. Pediatrics 1996, 98:301-304.
36. Kuczenski R., Segal D.S. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. Journal of Neuroscience 2002, 22:7264-7271.
37. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002, 27:699-711.
38. Mattiuz E.L., Ponsler G.D., Barbuch R.J., Wood P.G., Mullen J.H., Shugert R.L., et al. Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. Drug Metabolism and Disposition 2003, 31:88-97.
39. Hand D.J., Fox A.T., Reilly M.P. Response acquisition with delayed reinforcement in a rodent model of attention-deficit/hyperactivity disorder (ADHD). Behavioural Brain Research 2006, 175:337-342.
40. Floresco S.B., Ghods-Sharifi S., Vexelman C., Magyar O. Dissociable roles for the nucleus accumbens core and shell in regulating set shifting. Journal of Neuroscience 2006, 26:2449-2457.
41. Floresco S.B., Magyar O., Ghods-Sharifi S., Vexelman C., Tse M.T. Multiple dopamine receptor subtypes in the medial prefrontal cortex of the rat regulate set-shifting. Neuropsychopharmacology 2006, 31:297-309.
42. Kim J., Ragozzino M.E. The involvement of the orbitofrontal cortex in learning under changing task contingencies. Neurobiology of Learning and Memory 2005, 83:125-133.
43. Thai C.A., Zhang Y., Howland J.G. Effects of acute restraint stress on set-shifting and reversal learning in male rats. Cognitive, Affective, and Behavioral Neuroscience 2010, 13:164-173.
44. Zhang Y., Cazakoff B.N., Thai C.A., Howland J.G. Prenatal exposure to a viral mimetic alters behavioural flexibility in male, but not female, rats. Neuropharmacology 2012, 62:1299-1307.
45. Prusky G.T., Harker K.T., Douglas R.M., Whishaw I.Q. Variation in visual acuity within pigmented, and between pigmented and albino rat strains. Behavioural Brain Research 2002, 136:339-348.
46. Newman L.A., McGaughy J. Adolescent rats show cognitive rigidity in a test of attentional set shifting. Developmental Psychobiology 2011, 53:391-401.
47. Hill J.C., Herbst K., Sanabria F. Characterizing operant hyperactivity in the spontaneously hypertensive rat. Behavioral and Brain Functions 2012, 8:5.
48. Langen B., Dost R. Comparison of SHR WKY and Wistar rats in different behavioural animal models: effect of dopamine D1 and alpha2 agonists. Attention Deficit and Hyperactivity Disorders 2011, 3:1-12.
49. Johansen E.B., Sagvolden T., Kvande G. Effects of delayed reinforcers on the behavior of an animal model of attention-deficit/hyperactivity disorder (ADHD). Behavioural Brain Research 2005, 162:47-61.
50. Aase H., Sagvolden T. Infrequent, but not frequent, reinforcers produce more variable responding and deficient sustained attention in young children with attention-deficit/hyperactivity disorder (ADHD). Journal of Child Psychology and Psychiatry 2006, 47:457-471.
51. Rogers L.J., Bolden S.W., Patrech A.S., Ehrlich D. Visual dysfunction in the spontaneously hypertensive rat. Physiology and Behavior 1993, 54:903-907.
52. Johansen E.B., Aase H., Meyer A., Sagvolden T. Attention-deficit/hyperactivity disorder (ADHD) behaviour explained by dysfunctioning reinforcement and extinction processes. Behavioural Brain Research 2002, 130:37-45.
53. De Bruin N.M., Kiliaan A.J., De Wilde M.C., Broersen L.M. Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats. Neurobiology of Learning and Memory 2003, 80:63-79.
54. Jentsch J.D., Aarde S.M., Seu E. Effects of atomoxetine and methylphenidate on performance of a lateralized reaction time task in rats. Psychopharmacology (Berlin) 2009, 202:497-504.
55. Epstein J.N., Langberg J.M., Rosen P.J., Graham A., Narad M.E., Antonini T.N., et al. Evidence for higher reaction time variability for children with ADHD on a range of cognitive tasks including reward and event rate manipulations. Neuropsychology 2011, 25:427-441.
56. Hervey A.S., Epstein J.N., Curry J.F., Tonev S., Eugene Arnold L., Keith Conners C., et al. Reaction time distribution analysis of neuropsychological performance in an ADHD sample. Child Neuropsychology 2006, 12:125-140.
57. Drechsler R., Rizzo P., Steinhausen H.C. Decision making with uncertain reinforcement in children with attention deficit/hyperactivity disorder (ADHD). Child Neuropsychology 2010, 16:145-161.
58. Desman C., Petermann F., Hampel P. Deficit in response inhibition in children with attention deficit/hyperactivity disorder (ADHD): impact of motivation?. Child Neuropsychology 2008, 14:483-503.
59. Reeve W.V., Schandler S.L. Frontal lobe functioning in adolescents with attention deficit hyperactivity disorder. Adolescence 2001, 36:749-765.
60. Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neuroscience and Biobehavioral Reviews 2000, 24:31-39.
61. Barkley R.A., Edwards G., Laneri M., Fletcher K., Metevia L. Executive functioning, temporal discounting, and sense of time in adolescents with attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD). Journal of Abnormal Child Psychology 2001, 29:541-556.
62. Wehmeier P.M., Schacht A., Wolff C., Otto W.R., Dittmann R.W., Banaschewski T. Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tracking device. Journal of Child and Adolescent Psychopharmacology 2011, 21:433-444.
63. Sun H., Cocker P.J., Zeeb F.D., Winstanley C.A. Chronic atomoxetine treatment during adolescence decreases impulsive choice, but not impulsive action, in adult rats and alters markers of synaptic plasticity in the orbitofrontal cortex. Psychopharmacology (Berlin) 2011, 219:285-301.
64. Easton N., Marshall F., Fone K., Marsden C. Atomoxetine produces changes in cortico-basal thalamic loop circuits: assessed by phMRI BOLD contrast. Neuropharmacology 2007, 52:812-826.
65. Heal D.J., Smith S.L., Findling R.L. ADHD: current and future therapeutics. Current Topics in Behavioral Neurosciences 2012, 9:361-390.
66. Heal D.J., Smith S.L., Kulkarni R.S., Rowley H.L. New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD. Pharmacology Biochemistry and Behavior 2008, 90:184-197.
67. Crofts H.S., Dalley J.W., Collins P., Van Denderen J.C., Everitt B.J., Robbins T.W., et al. Differential effects of 6-OHDA lesions of the frontal cortex and caudate nucleus on the ability to acquire an attentional set. Cerebral Cortex 2001, 11:1015-1026.
68. Russell V., de Villiers A., Sagvolden T., Lamm M., Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder--the spontaneously hypertensive rat. Brain Research 1995, 676:343-351.
69. Berridge C.W., Devilbiss D.M., Andrzejewski M.E., Arnsten A.F., Kelley A.E., Schmeichel B., et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biological Psychiatry 2006, 60:1111-1120.
70. Blum N.J., Jawad A.F., Clarke A.T., Power T.J. Effect of osmotic-release oral system methylphenidate on different domains of attention and executive functioning in children with attention-deficit-hyperactivity disorder. Developmental Medicine and Child Neurology 2011, 53:843-849.
71. Salek R.L., Claussen C.M., Perez A., Dafny N. Acute and chronic methylphenidate alters prefrontal cortex neuronal activity recorded from freely behaving rats. European Journal of Pharmacology 2012, 679:60-67.
72. Berridge C.W., Shumsky J.S., Andrzejewski M.E., McGaughy J.A., Spencer R.C., Devilbiss D.M., et al. Differential sensitivity to psychostimulants across prefrontal cognitive tasks: differential involvement of noradrenergic alpha(1) - and alpha(2)-receptors. Biological Psychiatry 2012, 71:467-473.
73. Easton N., Marshall F.H., Marsden C.A., Fone K.C. Mapping the central effects of methylphenidate in the rat using pharmacological MRI BOLD contrast. Neuropharmacology 2009, 57:653-664.
74. Fumagalli F., Cattaneo A., Caffino L., Ibba M., Racagni G., Carboni E., et al. Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate. Pharmacological Research 2010, 62:523-529.
75. Wilens T.E., Hammerness P., Utzinger L., Schillinger M., Georgiopoulous A., Doyle R.L., et al. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. Journal of Child and Adolescent Psychopharmacology 2009, 19:485-492.
76. Brown T.E. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. Journal of Child and Adolescent Psychopharmacology 2004, 14:129-136.
77. Jaworowski S., Benarroch F., Gross-Tsur V. Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome. Journal of Child and Adolescent Psychopharmacology 2006, 16:365-370.
78. Robertson S.D., Matthies H.J., Galli A. A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Molecular Neurobiology 2009, 39:73-80.
79. Richelson E., Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. European Journal of Pharmacology 1984, 104:277-286.
80. Patrick K.S., Caldwell R.W., Ferris R.M., Breese G.R. Pharmacology of the enantiomers of threo-methylphenidate. Journal of Pharmacology and Experimental Therapeutics 1987, 241:152-158.
81. Soto P.L., Wilcox K.M., Zhou Y., Ator N.A., Riddle M.A., Wong D.F., et al. Long-term exposure to oral methylphenidate or dl-amphetamine mixture in peri-adolescent rhesus monkeys: effects on physiology, behavior, and dopamine system development. Neuropsychopharmacology 2012, 37:2566-2579.